AbbVie Inc. (ABBV) Stock Slides Amid Earnings Plunge Despite Revenue Growth
AbbVie Inc. shares tumbled 4.45% to $218.04 after reporting a staggering 88% drop in GAAP EPS to $0.10 for Q3. The decline overshadowed a 9.1% revenue increase to $15.776 billion, fueled by robust immunology and neuroscience sales.
Skyrizi and Rinvoq delivered standout performances, surging 46.8% and 35.3% respectively, offsetting Humira's 55.4% collapse due to biosimilar competition. Neuroscience products like Botox and Vraylar maintained double-digit growth, while aesthetics segment weakness dragged on margins.
The pharmaceutical giant raised its 2025 EPS guidance and dividend, signaling confidence in its long-term pipeline despite near-term earnings volatility. Market reaction suggests investors remain cautious about the transition from Humira's dominance to newer therapies.
